Cytodyn Inc (CYDY)

[SansBS]

Question for 3X, scooter, blackops, or anyone else with both securities/market knowledge and ability to think critically (I have very little of the former, but like to think some of the latter) :

CYDY shareholders deserve what they get. The opportunity to replace Nader was available and the shareholders inexplicably endorsed Nader and his new BOD placing the company on a trip down the drain. The 200m shares will fetch less and less as the SP cycles down on failed PRs and the realization there are no positive catalysts on the horizon. At $.60, which is probably the new number for a large raise, there is barely enough to cover Fife Dept and receivables, let alone monthly burn.

Outlook grim!

Is there any possibility of digging out of the abyss, clearly a result of years of NP's bad decisions and loss of credibility, by selling the HIV indication (exclusive to HIV), even if at a discount, to Gilead or one of their competitors? Assuming Gilead is on a mission to "own" that space, does LL have enough value in potential synergy with their drugs, or just eliminating another competitor, to justify a price that would get CYDY out of the woods in order to move forward with the other indications?
Although its both ironic and a travesty to reward someone (especially more than they've already been rewarded) for failure, ideally, some portion of the proceeds would be used to pay him to go away, for ever!!!

I still believe that replacing NP with a CEO who: had only moderate experience and success in Bio pharm, but was smart, had good business sense and credibility, a reputation for working well with others, and just 1/2 of NP's flaws and weaknesses; the company and the SP would benefit significantly.